JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Gabrielle Leclercq-CohenHélène HaegelAlberto TosoTina ZimmermannLuke GreenNathalie SteinhoffJohannes SamVesna PulkoAnneliese SchneiderAnna Maria GiustiJohn ChallierAnne Freimoser-GrundschoberLaurent LarivièreAlex OdermattMartin SternPablo UmanaMarina BacacChristiane NeumannPublished in: Journal for immunotherapy of cancer (2022)
Taken together, these data support further evaluation of the use of Src, JAK and mTOR inhibitors as prophylactic treatment to prevent occurrence of CRS.